Silence Therapeutics is a leading RNA therapeutics company. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.
Silence has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics.
Listed on London’s AIM since 2005 (AIM: SLN), and with operations in London and Berlin, Silence is one of very few listed companies globally with human validated RNA delivery systems. Its AtuRNAi® technology is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. It has been used in three Phase 2 clinical trials, two awaiting results. Delivery capability is key for the next stage in genetic medicine, targeting disease right at the cause.
Silence has an expanding early stage pipeline and collaborates with world leading research institutions to develop the most promising drug candidates. For more information, visit us at www.silence-therapeutics.com, or follow us on Twitter - @SilenceTheraPlc
Company Growth (employees)